scholarly journals Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

1995 ◽  
Vol 34 (2) ◽  
pp. 185-189 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
J. Verweij ◽  
R. de Wit ◽  
W. H. J. Kruit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Oral Etoposide ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Dose Oral ◽  
Line Chemotherapy

scholarly journals Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer

1992 ◽  
Vol 21 (2) ◽  
pp. 133-138 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
C. J. Rodenburg ◽  
A. Dees ◽  
J. Verweij ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Assessment of quality of life during second line chemotherapy for advanced breast cancer

1993 ◽  
Vol 29 ◽  
pp. S85
Author(s):  
E.E. Voest ◽  
P.H.Th. Slee ◽  
H. de Hses ◽  
S.G.L. van der Vegt ◽  
J.W.R. Nortier
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer

1991 ◽  
Vol 27 (6) ◽  
pp. 477-480 ◽  
Author(s):  
Hellmut Samonigg ◽  
Herbert St�ger ◽  
Anne-Katrin Kasparek ◽  
Marianne Schmid ◽  
Johann Dusleag ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

2019 ◽  
Vol 179 (3) ◽  
pp. 677-685
Author(s):  
Anouk K. M. Claessens ◽  
◽  
Reinier Timman ◽  
Jan J. Busschbach ◽  
Jeanette M. Bouma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Primary Objective ◽  
Advanced Breast ◽  
Continuous Treatment ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Small Decline ◽  
Line Chemotherapy

Abstract Background The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first- and second-line chemotherapy. Methods QoL was measured with RAND-36 questionnaires every 12 weeks. The primary objective was to estimate differences in changes from baseline between intermittent and continuous treatment. An effect size of 0.5 SD (5 points) was considered clinically meaningful. Results A total of 398 patients were included with a median follow-up of 11.4 months (IQR 5.6–22.2). Mean physical QoL baseline scores were 38.0 resp. 38.2, and mental scores 45.0 resp. 42.4 for intermittent and continuous treatment. Physical QoL declined linearly in the intermittent arm causing a clinically meaningful difference of 5.40 points at 24 months (p < 0.001), while scores in the continuous arm stabilized after a small decline of ± 3.4 points at 12 months. Conversely, mental QoL was fairly stable and even improved with 1.58 (p = 0.005) and 2.48 points (p < 0.001) at 12 months for intermittent and continuous treatment, respectively. When comparing arms for both components in changes from baseline, the maximum differences were 2.46 (p = 0.101) and 1.95 points (p = 0.182) for physical and mental scores, both measured at 30 months and in favor of continuous treatment. Conclusion Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course. We recommend prescribing chemotherapy continuously until progressive disease or unacceptable toxicity. Trial registration EudraCT 2010-021519-18; BOOG 2010-02

Ifosfamide, Mesna and Epirubicin as Second-Line Chemotherapy in Advanced Breast Cancer

1996 ◽  
Vol 8 (4) ◽  
pp. 310-314 ◽  
Author(s):  
S. Kıraz ◽  
E. Baltali ◽  
N. GüLer ◽  
İ. Barista ◽  
M. Beneklyı ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer

1986 ◽  
Vol 18 (2) ◽  
Author(s):  
Aaron Sulkes ◽  
Eliahu Gez ◽  
M.Raphael Pfeffer ◽  
Raphael Catane ◽  
Rut Isacson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C

1993 ◽  
Vol 26 (1) ◽  
pp. 49-53 ◽  
Author(s):  
W. Scheithauer ◽  
G. Kornek ◽  
K. Haider ◽  
W. Kwasny ◽  
T. Schenk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mitomycin C ◽  
Advanced Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Cisplatin and VP16 in Metastatic Breast Carcinoma as a Third-Line Chemotherapy: A Randomized Study Comparing Low versus High Doses of Cisplatin

1995 ◽  
Vol 81 (4) ◽  
pp. 241-244 ◽  
Author(s):  
Guido Ceci ◽  
Giancarlo Bisagni ◽  
Giorgio Cocconi ◽  
Carmelina Rodinò ◽  
Virginio Belsanti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Objective Response ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
High Dose ◽  
Severe Toxicity ◽  
Third Line ◽  
Line Chemotherapy

Aims and background The study was designed to define the activity of the combination of cisplatin and etoposide as third-line chemotherapy for advanced breast cancer and to investigate the role of the dosage of cisplatin on the effectiveness of the combination. Methods Ninety-five eligible patients with advanced breast cancer who had failed or relapsed on two previous lines of chemotherapy were randomized to receive cisplatin at a high dose (100 mg/m2 i.v. day 1, arm A) or a low dose (60 mg/m2 day 1, arm B), combined with etoposide (100 mg/m2 i.v. days 4, 6 and 8). Cycles were repeated every 3 weeks. Results Of the 78 patients evaluable for response (39 in arm A and 39 in arm B), 9 (12%) showed complete or partial response, 5 (13%) in the high-dose arm and 4 (10%) in the low-dose arm. One complete response was seen in the high-dose arm and none in the low-dose arm. The only 2 patients with brain involvement showed an objective response (one CR in arm A and one PR in arm B). Median time to progression was 14 weeks in arm A and 10 weeks in arm B, median duration of remission 28 and 34 weeks, and survival 36 and 35 weeks, respectively. The differences were not significant. As expected, the patients in the high-dose arm experienced more severe toxicity. One toxic death was observed in each arm due to sepsis in agranulocytosis. The difference was statistically significant regarding nausea and vomiting. Neurotoxicity and ototoxicity were not relevant problems in this patient setting. Conclusions Considering the very poor prognostic factors presented by these patients, the combination showed a certain activity, and further evaluation in earlier stages of disease is warranted. A particular responsiveness on brain metastases is suggested. The dose of cisplatin was not proven to be of significant importance.

Sign in / Sign up

Export Citation Format

Share Document